2024-11-01 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report 

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company developing and marketing a broad range of medicines in various therapeutic areas, including immunology, oncology, virology, neurology, and eye care. 

**1. Performance Comparison:**

* **Cumulative Return:** ABBV (164.98%) outperformed the S&P 500 (VOO, 131.38%) by 33.6 percentage points. 
* **Relative Outperformance:** ABBV's outperformance is currently at the 73.6th percentile relative to its historical performance against the S&P 500. 

**2. Recent Price Movements:**

* **Closing Price:** $203.87
* **5-day Moving Average:** $194.47
* **20-day Moving Average:** $192.24
* **60-day Moving Average:** $193.85 

**3. Technical Indicators:**

* **RSI:** 64.11 (Indicates a slightly overbought condition)
* **PPO:** 0.68 (Indicates a positive momentum)
* **Delta_Previous_Relative_Divergence:** +9.65 (Indicates a short-term upward trend)
* **Expected Return:** 1.51% (Expected long-term (2 years or more) outperformance over the S&P 500 for a buy-and-hold strategy)

**4. Recent Earnings and Outlook:**

| Date       | EPS | Expected EPS |
|-------------|-----|--------------|
| 2024-10-30 | 3   | 2.92         |
| 2024-07-25 | 2.65 | 2.57         |
| 2024-04-26 | 2.31 | 2.26         |
| 2024-02-02 | 2.79 | 2.76         |
| 2023-10-27 | 2.95 | 2.86         |

ABBV's most recent earnings for the quarter ending October 30, 2024, slightly beat analyst expectations with an EPS of 3 compared to the expected 2.92. ABBV has consistently exceeded earnings estimates in recent quarters, demonstrating its strong earnings power.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2024-06-30 | $14.46B  | 70.94%        |
| 2024-03-31 | $12.31B  | 66.74%        |
| 2023-12-31 | $14.30B  | 60.11%        |
| 2023-09-30 | $13.93B  | 53.44%        |
| 2023-06-30 | $13.87B  | 69.42%        |

ABBV demonstrates strong revenue growth and consistent profitability, with high profit margins over the past few quarters.

**2) Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2024-06-30 | $6.78B  | 20.21%  |
| 2024-03-31 | $8.01B  | 17.10%  |
| 2023-12-31 | $10.36B | 7.93%   |
| 2023-09-30 | $12.09B | 14.70%  |
| 2023-06-30 | $12.87B | 15.73%  |

ABBV's ROE has shown volatility in recent quarters, potentially indicating changes in its capital structure or profitability.

**6. News and Recent Issues:**

**Earnings News:** ABBV announced strong Q3 2024 earnings on October 30th, exceeding analysts' expectations. The company cited strong performance in its immunology and oncology segments as key drivers. 

**Recent Market Outlook:** 

Several analysts remain bullish on ABBV's long-term growth potential due to its strong pipeline of innovative drugs and its dominant market position in certain therapeutic areas. 

**Analyst Opinions and Performance Highlights:**

According to FINBOLD, ABBV is currently rated as "Buy" by 10 analysts, "Hold" by 6 analysts, and "Sell" by 0 analysts.  The average target price for ABBV is $195.47, suggesting potential downside from the current price.  

**7. Comprehensive Analysis:**

ABBV demonstrates strong performance with consistent revenue growth, high profitability, and a history of exceeding earnings expectations. Its outperformance against the S&P 500 and its positive technical indicators suggest potential for continued growth in the short term. However, its slightly overbought RSI and potential downside based on analyst target price should be considered.  

**8. Conclusion:**

Overall, ABBV appears to be a promising investment with a strong track record of profitability and potential for future growth. Long-term investors seeking exposure to the pharmaceutical sector might consider ABBV, given its strong fundamentals and favorable market position. 

**Disclaimer:** This report is intended for informational purposes only and does not constitute investment advice. Consult with a financial professional before making any investment decisions.
